Filing Flows › Fennec Pharmaceuticals (FENC) › Q3 2025
Fennec Pharmaceuticals (FENC) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Fennec Pharmaceuticals (FENC) reported revenue of $12.5M for the third quarter 2025 (Q3 2025), +79% from a year earlier and +29% from the quarter before. Operating margin was -1.5%, net loss $637K (5.1% of revenue).
Fennec Pharmaceuticals, Q3 2025: revenue $12.5M (+79% year over year), operating margin -1.5%, net loss $637K, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.5M | +29% | +79% |
| Operating profit | −$189K | — | — |
| Net earnings | −$637K | — | — |
| Operating cash flow | $1.5M | — | — |
What changed
Revenue was $12.5M in Q3 2025, up 79% year over year and up 29% from the previous quarter.
Operating costs exceeded revenue by $189K, an operating margin of -1.5%. Total costs grew 4% against revenue growth of 79%. The fastest-growing cost line was Sales & marketing (+13%). The quarter ended with a net loss of $637K, narrower than the previous quarter's $3.2M loss. Net interest and other expense of $448K was the main reason.
Operating cash flow was $1.5M. Non-cash charges added back $2.2M of share-based compensation. Working capital and other items used $89K.
Questions
What was Fennec Pharmaceuticals' revenue in the third quarter 2025?
Fennec Pharmaceuticals (FENC) reported revenue of $12.5M for the third quarter 2025 (Q3 2025), +79% from a year earlier and +29% from the quarter before.
Was Fennec Pharmaceuticals profitable in the third quarter 2025?
Operating loss was $189K (-1.5% of revenue) and net loss $637K.